Based on these observations, in vivo expansion of Foxp3+ Tregs using IL-2 and other methods has been explored as a potential therapeutic for human inflammatory bowel disease (IBD) (33, 34). This evidence concerns the gene FOXP3 and inflammatory bowel disease.